| Característica |
Objectiu de la convocatòria
The Alzheimer's Drug Discovery Foundation supports promising, diverse international research projects to develop new drugs for Alzheimer's and related dementias, including vascular, Lewy body, and frontotemporal dementias.
ADDF's goal is to accelerate the development of therapies through four core areas:
Drug discovery
Clinical trials
Biomarkers
Prevention
|
Característiques principals
FUNDING MECHANISMS:
Drug Discovery RFP: This RFP supports novel drug programs aiming to advance novel lead molecules to the clinical candidate selection stage (this includes small molecules and biologics -e.g., antibodies, peptides, gene therapies), and repurposed/repositioned programs aiming to build preclinical evidence in relevant animal models for repurposed drugs (existing drugs that are approved for other diseases and conditions) and repositioned drugs (existing drugs that have entered clinical trials for other indications and have not yet been approved).
Program to Accelerate Clinical Trials (PACT) RFP: This RFP funds early-stage clinical trials through phase 2 for novel drug candidates, proof-of-concept trials in patients for repurposed/repositioned drugs, and regulatory studies for IND/CTA preclinical packages and drug manufacturing for later stage trials.
Neuroimaging and CSF Biomarker Development RFP: This RFP supports the development and validation of neuroimaging and CSF biomarkers to enhance clinical trials for Alzheimer's disease, related dementias, and cognitive aging.
Prevention Beyond the Pipeline RFP: This RFP supports comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.
|
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.05.76.
Marta López: mlopez4@imim.es Ext.: 1576
Carol Barnwell: cbarnwell@imim.es Ext.: 1670
|
Convocatòria (URL)
https://www.alzdiscovery.org/research-and-grants/funding-opportunities
|
Dotació
Drug discovery: $150,000 - $600,000
Program to accelerate clinical trials : up to $5 million
Neuroimaging and CSF biomarker development program: $150,000 - $600,000
Prevention beyond the pipeline: $50,000-$100,000 (epidemiological analyses), up to $3 million
|
Durada
Drug discovery: 1 year, potential for follow-up funding
Program to accelerate clinical trials : multi-year
Biomarkers development: 1-2 years, potential for follow-up funding
Prevention beyond the pipeline: 1 year (epidemiological analyses), multi-year (clinical trials)
|
AVÍS IMPORTANT
Deadlines for 2019 RFPs:
LETTERS OF INTENT:
January 18,
April 12
July 12
October 11
INVITED FULL PROPOSALS:
February 8
May 10
August 9
November 8
|